A Novel Approach to Essential Thrombocythemia and Cardiac Surgery

Bradford B. Smith; Gregory A. Nuttall; Rajiv K. Pruthi; David L. Joyce; Matthew S. Schuldes; Mark M. Smith

doi:10.1016/j.athoracsur.2016.08.065

A Novel Approach to Essential Thrombocythemia and Cardiac Surgery

Bradford B. Smith, Gregory A. Nuttall, Rajiv K. Pruthi, David L. Joyce, Matthew S. Schuldes, Mark M. Smith

Cardiovascular Surgery

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent thrombocytosis (>450 × 10⁹/L). Patients with ET are at risk for thrombotic or hemorrhagic complications especially during cardiovascular operations. We discuss a patient with ET requiring coronary artery bypass grafting with a presenting platelet count of 1631 × 10⁹/L. Platelet reduction with an intraoperative autologous transfusion technique decreased the platelet count to 758 × 10⁹/L before initiation of cardiopulmonary bypass. In addition, perioperative cangrelor therapy was administered to further limit risk of thrombotic complications. The patient had an uneventful perioperative and postoperative course.

Original language	English (US)
Pages (from-to)	e249-e250
Journal	Annals of Thoracic Surgery
Volume	103
Issue number	3
DOIs	https://doi.org/10.1016/j.athoracsur.2016.08.065
State	Published - Mar 1 2017

ASJC Scopus subject areas

Surgery
Pulmonary and Respiratory Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.athoracsur.2016.08.065

Cite this

@article{3e02254940d44d11a09e4ef03b7b258a,

title = "A Novel Approach to Essential Thrombocythemia and Cardiac Surgery",

abstract = "Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent thrombocytosis (>450 × 109/L). Patients with ET are at risk for thrombotic or hemorrhagic complications especially during cardiovascular operations. We discuss a patient with ET requiring coronary artery bypass grafting with a presenting platelet count of 1631 × 109/L. Platelet reduction with an intraoperative autologous transfusion technique decreased the platelet count to 758 × 109/L before initiation of cardiopulmonary bypass. In addition, perioperative cangrelor therapy was administered to further limit risk of thrombotic complications. The patient had an uneventful perioperative and postoperative course.",

author = "Smith, {Bradford B.} and Nuttall, {Gregory A.} and Pruthi, {Rajiv K.} and Joyce, {David L.} and Schuldes, {Matthew S.} and Smith, {Mark M.}",

note = "Publisher Copyright: {\textcopyright} 2017 The Society of Thoracic Surgeons",

year = "2017",

month = mar,

day = "1",

doi = "10.1016/j.athoracsur.2016.08.065",

language = "English (US)",

volume = "103",

pages = "e249--e250",

journal = "Annals of Thoracic Surgery",

issn = "0003-4975",

publisher = "Elsevier USA",

number = "3",

}

TY - JOUR

T1 - A Novel Approach to Essential Thrombocythemia and Cardiac Surgery

AU - Smith, Bradford B.

AU - Nuttall, Gregory A.

AU - Pruthi, Rajiv K.

AU - Joyce, David L.

AU - Schuldes, Matthew S.

AU - Smith, Mark M.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent thrombocytosis (>450 × 109/L). Patients with ET are at risk for thrombotic or hemorrhagic complications especially during cardiovascular operations. We discuss a patient with ET requiring coronary artery bypass grafting with a presenting platelet count of 1631 × 109/L. Platelet reduction with an intraoperative autologous transfusion technique decreased the platelet count to 758 × 109/L before initiation of cardiopulmonary bypass. In addition, perioperative cangrelor therapy was administered to further limit risk of thrombotic complications. The patient had an uneventful perioperative and postoperative course.

AB - Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent thrombocytosis (>450 × 109/L). Patients with ET are at risk for thrombotic or hemorrhagic complications especially during cardiovascular operations. We discuss a patient with ET requiring coronary artery bypass grafting with a presenting platelet count of 1631 × 109/L. Platelet reduction with an intraoperative autologous transfusion technique decreased the platelet count to 758 × 109/L before initiation of cardiopulmonary bypass. In addition, perioperative cangrelor therapy was administered to further limit risk of thrombotic complications. The patient had an uneventful perioperative and postoperative course.

UR - http://www.scopus.com/inward/record.url?scp=85013131062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013131062&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2016.08.065

DO - 10.1016/j.athoracsur.2016.08.065

M3 - Article

C2 - 28219560

AN - SCOPUS:85013131062

SN - 0003-4975

VL - 103

SP - e249-e250

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

IS - 3

ER -

A Novel Approach to Essential Thrombocythemia and Cardiac Surgery

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this